Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Tofacitinib
Xeljanz
Routinely available
SMC (SMC2116)
29/03/2023
Indication
In combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
5mg film-coated tablet
Comments
-